Effect of LY294002 on survival of B-CLL lymphocytes
| Patient . | Viability (%) . | |||||
|---|---|---|---|---|---|---|
| Control . | LY294002 . | TPA . | LY294002 + TPA . | IL-4 . | LY294002 + IL-4 . | |
| 1 | 46 ± 7 | 22 ± 2 | 64 ± 12 | 38 ± 14 | 77 ± 1 | 66 ± 1 |
| 2 | 50 ± 11 | 20 ± 8 | 54 ± 17 | 34 ± 9 | 35 ± 1 | 26 ± 0.4 |
| 3 | 49 ± 12 | 12 ± 5 | 77 ± 2 | 42 ± 11 | 62 ± 2 | 32 ± 19 |
| 6 | 70 ± 1 | 35 ± 2 | 75 ± 0.3 | 45 ± 0.5 | 78 ± 1 | 60 ± 1 |
| 8 | 72 ± 1 | 60 ± 15 | 69 ± 1 | 57 ± 15 | 78 ± 1 | 70 ± 0.3 |
| 9 | 75 ± 6 | 35 ± 20 | 72 ± 6 | 67 ± 7 | 80 ± 3 | 67 ± 10 |
| 10 | 76 ± 11 | 35 ± 12 | 72 ± 10 | 49 ± 4 | 72 ± 10 | 49 ± 20 |
| 12 | 43 ± 6 | 5 ± 0.4 | 72 ± 4 | 45 ± 0.3 | 69 ± 2 | 24 ± 2 |
| Mean ± SD | 60 ± 5 | 28 ± 6* | 69 ± 3 | 47 ± 4† | 69 ± 5 | 49 ± 7‡ |
| Patient . | Viability (%) . | |||||
|---|---|---|---|---|---|---|
| Control . | LY294002 . | TPA . | LY294002 + TPA . | IL-4 . | LY294002 + IL-4 . | |
| 1 | 46 ± 7 | 22 ± 2 | 64 ± 12 | 38 ± 14 | 77 ± 1 | 66 ± 1 |
| 2 | 50 ± 11 | 20 ± 8 | 54 ± 17 | 34 ± 9 | 35 ± 1 | 26 ± 0.4 |
| 3 | 49 ± 12 | 12 ± 5 | 77 ± 2 | 42 ± 11 | 62 ± 2 | 32 ± 19 |
| 6 | 70 ± 1 | 35 ± 2 | 75 ± 0.3 | 45 ± 0.5 | 78 ± 1 | 60 ± 1 |
| 8 | 72 ± 1 | 60 ± 15 | 69 ± 1 | 57 ± 15 | 78 ± 1 | 70 ± 0.3 |
| 9 | 75 ± 6 | 35 ± 20 | 72 ± 6 | 67 ± 7 | 80 ± 3 | 67 ± 10 |
| 10 | 76 ± 11 | 35 ± 12 | 72 ± 10 | 49 ± 4 | 72 ± 10 | 49 ± 20 |
| 12 | 43 ± 6 | 5 ± 0.4 | 72 ± 4 | 45 ± 0.3 | 69 ± 2 | 24 ± 2 |
| Mean ± SD | 60 ± 5 | 28 ± 6* | 69 ± 3 | 47 ± 4† | 69 ± 5 | 49 ± 7‡ |
B-CLL cells were incubated for 48 hours in medium alone (control), with 10 nM TPA or 10 ng/mL IL-4, in the absence or presence of 20 μM LY294002. Cell viability was determined by flow cytometry. Data are shown as the mean ± SD of 2 or 3 independent experiments performed in duplicate.
P < .005 versus control.
P < .005 versus TPA.
P < .01 versus IL-4.